GSK-3052230
- Generic Name
- GSK-3052230
Study to Evaluate GSK3052230 in Combination With Paclitaxel and Carboplatin, or Docetaxel or as Single Agent in Subjects With Solid Malignancies and Deregulated Fibroblast Growth Factor (FGF) Pathway Signaling
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 65
- Registration Number
- NCT01868022
- Locations
- 🇬🇧
GSK Investigational Site, Nottingham, United Kingdom
Study of FP-1039 in Subjects With Endometrial Cancers
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Registration Number
- NCT01244438
Safety Study of FP-1039 To Treat Cancer
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2021-12-13
- Lead Sponsor
- Five Prime Therapeutics, Inc.
- Target Recruit Count
- 39
- Registration Number
- NCT00687505
- Locations
- 🇺🇸
Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸START (South Texas Accelerated Research Therapeutics), San Antonio, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath